Editas Medicine, Inc. EVP and Chief Scientific Officer Linda Burkly filed a Form 4 on November 6, 2026, disclosing the acquisition of 16,533 shares of common stock through the vesting of a performance-based restricted stock unit award tied to a research and development milestone.

Key Highlights

  • Shares acquired: 16,533 shares of Editas Medicine common stock were acquired on November 5, 2026, at a price of $0.
  • Transaction type: The acquisition (code A) reflects vesting of a performance-based restricted stock unit award originally granted on March 2, 2024.
  • Vesting trigger: According to the filing, the shares vested "upon the achievement of a specified research and development milestone."
  • Resulting ownership: Following the transaction, Burkly directly beneficially owns 78,193 shares of common stock.
  • Reporting person's role: Linda Burkly is identified as EVP, Chief Scientific Officer of Editas Medicine, Inc. (NASDAQ:EDIT).

Burkly's Performance RSU Vests Following R&D Milestone at Editas Medicine

Linda Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine, Inc. (NASDAQ:EDIT), reported the acquisition of 16,533 shares of the company's common stock on November 5, 2026, according to a Form 4 filed with the U.S. Securities and Exchange Commission on November 6, 2026. The transaction was recorded with a price of $0, consistent with the nature of a restricted stock unit vesting event.

The filing states that the shares represent "the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on March 2, 2024." The transaction code recorded is A (acquisition), and ownership is listed as direct. No derivative securities transactions were reported in Table II of the filing.

Following this transaction, Burkly's direct beneficial ownership in Editas Medicine common stock stands at 78,193 shares, as reported in the filing. The Form 4 was signed by Linda C. Burkly and submitted on November 6, 2026. No amendment date was indicated, and the filing was made by one reporting person.

What Was Disclosed

The filing disclosed the vesting of 16,533 shares of Editas Medicine common stock to EVP and Chief Scientific Officer Linda Burkly on November 5, 2026, triggered by an R&D milestone, bringing her direct beneficial ownership to 78,193 shares.